Table 2.
Event rates and odds of events by type of cardiomyopathy (n=27)*
| Event and type of cardiomyopathy | n | Event rate (%) | Unadjusted OR | Adjusted OR† | 95% CI | P value |
| SVT | ||||||
| Non-ischaemic | 9 | 33.3 | 1.0 | 1.0 | – | – |
| Ischaemic | 9 | 44.4 | 1.60 | 1.48 | 0.17 to 13.17 | 0.73 |
| Chemotherapy induced | 9 | 44.4 | 1.60 | 1.89 | 0.17 to 21.03 | 0.61 |
| NSVT | ||||||
| Non-ischaemic | 9 | 33.3 | 1.0 | 1.0 | – | – |
| Ischaemic | 9 | 77.8 | 7.00 | 8.95 | 0.90 to 88.94 | 0.06 |
| Chemotherapy induced | 9 | 44.4 | 1.60 | 2.10 | 0.21 to 20.56 | 0.53 |
| NSVT and/or sustained VT/VF | ||||||
| Non-ischaemic | 9 | 44.4 | 1.0 | 1.0 | – | – |
| Ischaemic | 9 | 88.9 | 10.00 | 28.60 | 1.26 to 648.2 | 0.04 |
| Chemotherapy induced | 9 | 44.4 | 1.00 | 2.70 | 0.25 to 29.48 | 0.42 |
*Non-ischaemic cardiomyopathy used as the comparator group.
†Adjusted for days since implantable cardioverter defibrillator (ICD) implant, history of atrial fibrillation and length of follow-up.
NSVT, non-sustained ventricular tachycardia; SVT, supraventricular tachycardia (includes atrial fibrillation); VF, ventricular fibrillation; VT, ventricular tachycardia.